Addex Therapeutics Ltd
ADXN.SW·Swiss·Healthcare
0.02080.0000 (0.00%)today
At close: Oct 28, 2:55 PM CET · May be delayed up to 15 min · CHF
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close0.0208
Open0.0208
Day range0.02080.0210
52-week range0.01800.0690
Off day high−0.95%
Off 52-week high−69.86%
Volume297.78K
Avg. volume (3M)896.22K
Market cap4.37M
EPS (TTM)-0.0500
Forward P/E-0.52
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)2.02
Shares outstanding210.29M
Short interest—
Earnings dateSep 28, 2026 (est.)
Analyst target—
Profit margin0.00%
Against its peers
Compare in full ›| ADXN.SW | GANX | SILO | MTVA | ENSC | QNTM | |
|---|---|---|---|---|---|---|
| Market cap | 4.37M | 51.50M | 2.97M | 7.64M | 8.80M | 15.33M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.5 | -1.7 | -1.9 | — | -9.0 | -0.3 |
| Price/book | 1.4 | 4.5 | 0.3 | 1.1 | -9.4 | 2.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −67.80% | −35.71% | −84.01% | −89.43% | −78.47% | −81.95% |
| Today | 0.00% | +0.85% | +4.65% | +0.86% | +0.56% | +2.80% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ADXN.SW news ›Clene (NASDAQ:CLNN) vs. Addex Therapeutics (NASDAQ:ADXN) Financial Comparison
Posted by Tristan Rich on Oct 22nd, 2026 Addex Therapeutics (NASDAQ:ADXN – Get Free Report) and Clene (NASDAQ:CLNN – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two…
From articles in the 4Search news index.
In the news
8mentions in 30 days
6with it in the headline
Positivesentiment
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net2
- manilatimes.net1
- news.alphastreet.com1
- pharmabiz.com1
- pulse2.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.